PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Amneal Pharmaceuticals, Inc. (AMRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US03168L1052

CUSIP

03168L105

Sector

Healthcare

IPO Date

Jan 15, 2009

Highlights

Market Cap

$3.63B

EPS (TTM)

-$0.86

Total Revenue (TTM)

$2.06B

Gross Profit (TTM)

$757.57M

EBITDA (TTM)

$344.43M

Year Range

$5.01 - $9.48

Target Price

$10.50

Short %

0.94%

Short Ratio

2.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AMRX vs. CORT AMRX vs. AXP
Popular comparisons:
AMRX vs. CORT AMRX vs. AXP

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Amneal Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-5.00%0.00%5.00%10.00%SeptemberOctoberNovemberDecember2025February
-3.57%
9.31%
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Amneal Pharmaceuticals, Inc. had a return of -0.88% year-to-date (YTD) and 35.81% in the last 12 months. Over the past 10 years, Amneal Pharmaceuticals, Inc. had an annualized return of -15.13%, while the S&P 500 had an annualized return of 11.31%, indicating that Amneal Pharmaceuticals, Inc. did not perform as well as the benchmark.


AMRX

YTD

-0.88%

1M

-4.96%

6M

-3.56%

1Y

35.81%

5Y*

11.09%

10Y*

-15.13%

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of AMRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20254.29%-0.88%
2024-11.86%3.18%9.78%-0.17%10.41%-4.94%15.43%18.14%-3.93%1.80%-2.36%-4.23%30.48%
202310.55%-6.36%-32.52%38.85%21.24%32.48%3.23%27.81%3.18%-8.29%11.37%40.84%205.03%
2022-7.52%2.26%-7.95%-7.43%-5.96%-12.40%11.32%-38.70%-6.91%8.91%16.36%-22.27%-58.46%
20215.25%12.06%24.86%-18.13%2.72%-9.54%-3.71%14.40%-5.32%2.81%-23.86%14.59%4.81%
2020-6.85%-14.25%-9.61%4.31%34.16%-2.26%-9.03%-5.08%-5.60%7.22%-5.05%15.70%-5.19%
2019-9.24%10.18%4.73%-9.17%-41.41%-4.91%-48.95%-30.33%13.73%6.21%22.08%28.19%-64.38%
201816.82%4.88%-4.66%-3.34%5.00%-16.87%16.82%20.50%-3.94%-16.85%-4.01%-23.60%-18.74%
2017-0.75%8.37%-11.23%11.07%8.54%5.57%20.19%11.89%-6.24%-10.59%-8.26%-0.00%25.66%
2016-12.37%-12.76%-2.05%4.15%2.40%-15.61%9.02%-23.01%-2.03%-15.19%-28.11%-8.30%-69.01%
201515.75%9.87%16.33%-3.44%3.87%-2.32%5.53%-15.48%-14.04%-1.65%27.23%-2.95%34.97%
2014-7.96%11.37%2.52%-1.02%6.16%8.03%-22.01%5.34%-3.77%22.18%10.29%-0.85%26.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AMRX is 71, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AMRX is 7171
Overall Rank
The Sharpe Ratio Rank of AMRX is 7474
Sharpe Ratio Rank
The Sortino Ratio Rank of AMRX is 7474
Sortino Ratio Rank
The Omega Ratio Rank of AMRX is 6767
Omega Ratio Rank
The Calmar Ratio Rank of AMRX is 6262
Calmar Ratio Rank
The Martin Ratio Rank of AMRX is 7777
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for AMRX, currently valued at 0.88, compared to the broader market-2.000.002.000.881.74
The chart of Sortino ratio for AMRX, currently valued at 1.71, compared to the broader market-4.00-2.000.002.004.006.001.712.35
The chart of Omega ratio for AMRX, currently valued at 1.18, compared to the broader market0.501.001.502.001.181.32
The chart of Calmar ratio for AMRX, currently valued at 0.37, compared to the broader market0.002.004.006.000.372.61
The chart of Martin ratio for AMRX, currently valued at 4.24, compared to the broader market0.0010.0020.0030.004.2410.66
AMRX
^GSPC

The current Amneal Pharmaceuticals, Inc. Sharpe ratio is 0.88. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Amneal Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50SeptemberOctoberNovemberDecember2025February
0.88
1.74
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Amneal Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-84.70%
0
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Amneal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amneal Pharmaceuticals, Inc. was 97.52%, occurring on Mar 28, 2023. The portfolio has not yet recovered.

The current Amneal Pharmaceuticals, Inc. drawdown is 84.70%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.52%Apr 16, 20152002Mar 28, 2023
-48.49%May 11, 2011456Mar 5, 2013317Jun 6, 2014773
-36.82%Feb 23, 200932Apr 7, 200974Jul 23, 2009106
-27.71%Jun 16, 201054Aug 31, 201030Oct 13, 201084
-25.93%Jul 2, 201423Aug 4, 201477Nov 20, 2014100

Volatility

Volatility Chart

The current Amneal Pharmaceuticals, Inc. volatility is 8.42%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
8.42%
3.07%
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Amneal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Amneal Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab